The 3DKnee™ System: A Post-Market Study

Encore Medical, L.P.71 enrolled

Overview

The purpose of this study is to evaluate the survivorship and efficacy of the Encore 3DKnee™ system in a group of patients who will receive the 3DKnee™ as a primary (first) orthopedic implant in the knee. Each knee will be designated as a separate subject and followed for a period of 2 years.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Osteoarthritis Rheumatoid Arthritis Post Traumatic Arthritis Varus Deformity Avascular Necrosis

Interventions

3DKneeDEVICE

Subjects with knee osteoarthritis and willing to participate in the study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * This must be a primary knee replacement on this knee. * Have knee joint disease related to one or more of the following * degenerative joint disease, including osteoarthritis or traumatic arthritis * Avascular necrosis of the femoral condyles * Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy * Moderate valgus, varus, or flexion deformities * Rheumatoid arthritis * Patient is likely to be available for evaluation for the duration of the study * Able and willing to sign the informed consent and follow study procedures * Patient is not pregnant * Patient must be over 18 years of age Exclusion Criteria: * If there has been a total knee replacement on this knee in the past (no revisions allowed in study) * Infection, or history of infection, acute or chronic, local or systemic * Alcoholism or other addictions * Muscular, neurological or vascular deficiencies which compromise the affected extremity * Obesity * Insufficient bone quality * Loss of ligamentous structures * High levels of physical activity * Materials sensitivity * Prisoner * Mental conditions that may interfere with the patient's ability to give an informed consent or willingness to fulfill the study requirements * Patient is pregnant * Is younger than 18 years of age

Locations (1)

St. Peter's Bone & Joint Surgery

City of Saint Peters, Missouri, United States

Outcomes

Primary Outcomes

Knee Society Score Evaluation

The Knee Society Score includes a knee rating and function score. This evaluation covers the knee rating score with three main parameters of pain, stability and range of motion and that flexion contracture, extension lag and misalignment should be dealt with as deductions. Thus, 100 points will be obtained by a well-aligned knee with no pain, 125 degrees of motion, and negligible anteroposterior and mediolateral instability. 50 points are allotted for pain, 25 for stability, and 25 for range of motion. Grading for KS Score: Excellent (90-100), Good (80-90), Fair (70-79) and Poor (\<70).

Time frame: 2 year

Knee Society Function Score

The Knee Society Score includes a knee rating and function score. Patient function considers only walking distance and stair climbing, with deductions for walking aids. The maximum function score, which is also 100, is obtained by a patient who can walk an unlimited distance and go up and down stairs normally. Walking ability is expressed in blocks (approximately 100 meters). Stair climbing is considered normal if the patient can ascend and descend stairs without holding a railing. A score of \> or = to 60 on the function score is considered success.

Time frame: 2-year

Number of Participants With >2mm Wide at the Bone/Cement Interface or a >3 Degree or >3 mm Migration (Shift) of the Component.

Radiographic failure is defined as a complete radiolucent line \> 2mm wide at the bone/cement interface or a \>3 degree or \>3 mm migration (shift) of the component.

Time frame: 2-year

Safety Assessment

Number of device related adverse events and device failures at the 2 year time frame.

Time frame: 2-year

Secondary Outcomes

Oxford Knee Score

Questionnaire on the perceptions of patients about a total knee replacement. Score between 0 and 48 where: 0 to 19 may indicate severe knee arthritis, 20 to 29 may indicate moderate to severe knee arthritis, 30 to 39 may indicate mild to moderate knee arthritis and 40 to 48 may indicate satisfactory joint function.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.